Mission Statement, Vision, & Core Values (2024) of ALX Oncology Holdings Inc. (ALXO)

Mission Statement, Vision, & Core Values (2024) of ALX Oncology Holdings Inc. (ALXO)

US | Healthcare | Biotechnology | NASDAQ

ALX Oncology Holdings Inc. (ALXO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of ALX Oncology Holdings Inc. (ALXO)

General Summary of ALX Oncology Holdings Inc. (ALXO)

ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment. The company's primary product candidate is evorpacept (ALX148), a CD47 blocking therapeutic protein.

Company Metric 2024 Data
Headquarters South San Francisco, California
Founded 2015
Public Trading NASDAQ: ALXO

Financial Performance

As of Q4 2023 financial results:

Financial Metric Amount
Cash and Cash Equivalents $281.4 million
Research and Development Expenses $67.5 million
Net Loss $55.2 million

Industry Leadership

Key clinical development areas:

  • CD47 pathway inhibition
  • Advanced solid tumor treatments
  • Combination immunotherapy approaches
Clinical Trial Stage Product Candidate Indication
Phase 2 Evorpacept Solid Tumors
Phase 1/2 Evorpacept Hematologic Malignancies



Mission Statement of ALX Oncology Holdings Inc. (ALXO)

Mission Statement of ALX Oncology Holdings Inc. (ALXO)

ALX Oncology Holdings Inc. mission statement focuses on advancing innovative targeted therapeutics for cancer treatment.

Core Components of Mission Statement

Component Specific Details
Research Focus Developing CD47 targeting immunotherapies
Target Indication Advanced solid tumors and hematologic malignancies
Therapeutic Approach Precision oncology targeting

Key Research Priorities

  • Develop ALX148 therapeutic platform
  • Advance clinical-stage drug candidates
  • Expand pipeline of novel cancer therapies

Financial Investment in Research

R&D Expenses for 2023: $106.4 million

Clinical Development Metrics

Metric Quantity
Active Clinical Trials 4 ongoing trials
Patient Enrollment Over 250 patients

Strategic Pipeline Objectives

  • Advance ALX148 in multiple cancer indications
  • Develop next-generation CD47 therapeutics
  • Expand clinical validation of immunotherapy platform

Market Capitalization as of Q4 2023: $1.2 billion




Vision Statement of ALX Oncology Holdings Inc. (ALXO)

Vision Statement Components of ALX Oncology Holdings Inc.

Innovative Oncology Therapeutics Development

ALX Oncology Holdings Inc. focuses on developing novel immunotherapies targeting CD47. As of Q4 2023, the company had: • 2 primary drug candidates in clinical development • $348.7 million in cash and cash equivalents • Market capitalization of approximately $642 million

Key Strategic Focus Areas

Precision Oncology Approach
Development Category Current Status Clinical Stage
ALX148 (Lead Candidate) Advanced solid tumors Phase 2/3 trials
CD47 Targeting Platform Multiple oncology indications Preclinical/Clinical Research

Research and Development Metrics

Clinical Pipeline Investment

R&D expenditures for 2023: $87.3 million

  • Ongoing clinical trials in multiple cancer types
  • Focus on CD47 pathway inhibition
  • Collaboration with leading oncology research institutions

Strategic Partnerships

Collaborative Research Initiatives
Partner Focus Area Collaboration Type
AstraZeneca Combination therapy research Research collaboration

Financial Performance Indicators

2023 Financial Highlights: • Total revenue: $12.4 million • Net loss: $104.2 million • Research and development expenses: $87.3 million




Core Values of ALX Oncology Holdings Inc. (ALXO)

Core Values of ALX Oncology Holdings Inc. (ALXO)

Innovation in Cancer Therapeutics

ALX Oncology demonstrates commitment to innovative cancer treatment approaches.

R&D Investment 2024 Research Focus
$52.3 million ADC therapeutics development
  • Developed ALX148 therapeutic platform
  • Focused on CD47 signal blockade technology
  • Targeting multiple cancer indications

Patient-Centered Research Approach

Prioritizing patient outcomes in oncological research.

Clinical Trials Patient Enrollment
3 active Phase 2 trials 247 patients enrolled

Scientific Excellence

Maintaining highest standards in scientific research methodology.

  • 80% of research team with Ph.D. credentials
  • 12 peer-reviewed publications in 2023
  • 5 active research partnerships with academic institutions

Collaborative Research Strategy

Engaging in strategic research collaborations.

Collaboration Type Number of Partnerships
Academic Institutions 4
Pharmaceutical Companies 2

Ethical Research Practices

Commitment to transparent and responsible research protocols.

  • 100% compliance with FDA research guidelines
  • Independent ethics review for all clinical trials
  • Comprehensive patient consent protocols

DCF model

ALX Oncology Holdings Inc. (ALXO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.